{"disease":{"id":"adult-growth-hormone-deficiency","name":"Adult growth hormone deficiency","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of adult-onset growth hormone deficiency.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Adult Growth Hormone Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"somapacitan-beco","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"somapacitan","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05718570","title":"A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01580605","title":"French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin","phase":"","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02229851","title":"Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT05171855","title":"A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Ascendis Pharma Endocrinology Division A/S","has_results":true},{"nct_id":"NCT06694506","title":"BELux Children OutcoME During A(@)Dulthood With GHD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT05230550","title":"Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04867317","title":"Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT00519558","title":"Growth Hormone Deficiency in Adults (GHDA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07259564","title":"A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00184743","title":"Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01514500","title":"First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02382939","title":"A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT00931476","title":"A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07016802","title":"A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03075644","title":"A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT03186495","title":"Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02719990","title":"Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Versartis Inc.","has_results":true},{"nct_id":"NCT01706783","title":"A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03212131","title":"Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05979480","title":"The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":25,"lead_sponsor_name":"University Hospital Birmingham","has_results":false},{"nct_id":"NCT01562834","title":"Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT01698944","title":"Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}